Mandate

Vinge has advised Lifco AB (publ)

March 17, 2016

Vinge has advised Lifco AB (publ) and its wholly owned subsidiary Sorb Industri AB in connection with its acquisition of the majority of the Norwegian company Cenika AS. Lifco acquires and develops market-leading niche businesses with the potential to deliver sustainable profit growth and robust cash flows. The Group has three business areas: Dental, Demolition & Tools and Systems Solutions. The Lifco Group comprises 133 companies in 28 countries. In 2015 the Group reported EBITA of MSEK 1,186 on sales of around BSEK 7.9, with an EBITA margin of 15.0%. Cenika is a leading supplier of low voltage electrical supplies with sales directly to the professional power industry in Norway and Sweden. In 2015, Cenika’s sales amounted to approximately 160 MNOK.

The Vinge team included partner Erik Gabrielson and associate Mattias Sköld.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024